Kindred Biosciences, Inc. (KIN) financial statements (2022 and earlier)

Company profile

Business Address 1555 BAYSHORE HIGHWAY, SUITE 200
BURLINGAME, CA 94010
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:59,90073,50073,90082,51956,75573,043101,027
Cash and cash equivalents11,62015,98656,30234,8136,68719,99212,969
Short-term investments46,75855,72317,63046,20750,06853,05188,058
Other undisclosed cash, cash equivalents, and short-term investments1,5221,791(32)1,499   
Receivables624923903    
Inventory, net of allowances, customer advances and progress billings2074,2183,570    
Inventory2074,2183,570    
Other undisclosed current assets1,8937041,696(702)1,282712477
Total current assets:62,62479,34580,06981,81758,03773,755101,504
Noncurrent Assets
Operating lease, right-of-use asset3,4283,001
Property, plant and equipment28,20429,77726,3437,4572,4411,244394
Long-term investments and receivables1,5001,837 1,4991,0524,590 
Long-term investments1,5001,837 1,4991,0524,590 
Other noncurrent assets58647049463022
Total noncurrent assets:33,19034,67926,4139,0053,5395,864416
TOTAL ASSETS:95,814114,024106,48290,82261,57679,619101,920
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4,9609,58015,1816,0273,8673,2082,852
Accounts payable1451,2563,5761,439410717420
Accrued liabilities2,7454,1318,1691,9001,650569975
Employee-related liabilities2,0704,1933,4362,6881,8071,9221,457
Debt1,111644     
Other undisclosed current liabilities825      
Total current liabilities:6,89610,22415,1816,0273,8673,2082,852
Noncurrent Liabilities
Long-term debt and lease obligation21,43621,879     
Long-term debt, excluding current maturities18,50219,265     
Operating lease, liability2,9342,614
Liabilities, other than long-term debt  94115294044
Accounts payable and accrued liabilities  94115294044
Other undisclosed noncurrent liabilities(2,934)      
Total noncurrent liabilities:21,43621,87994115294044
Total liabilities:28,33232,10315,2756,1423,8963,2482,896
Stockholders' equity
Stockholders' equity attributable to parent, including:67,48281,92191,20784,68057,68076,37199,024
Common stock4433222
Additional paid in capital312,321304,963252,885196,688138,810135,021130,521
Accumulated other comprehensive income (loss)1213(11)(31)(31)(50)(27)
Accumulated deficit(244,855)(223,059)(161,670)(111,980)(81,101)(58,602) 
Other undisclosed stockholders' equity attributable to parent      (31,472)
Total stockholders' equity:67,48281,92191,20784,68057,68076,37199,024
TOTAL LIABILITIES AND EQUITY:95,814114,024106,48290,82261,57679,619101,920

Income statement (P&L) ($ in thousands)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues42,1644,2561,966    
Cost of revenue
(Cost of Goods and Services Sold)
(4,626)(587)(324)    
Gross profit:37,5383,6691,642    
Operating expenses(57,506)(66,448)(53,222)(31,653)(22,824)(27,262)(27,233)
Other undisclosed operating income 212324    
Operating loss:(19,968)(62,567)(51,256)(31,653)(22,824)(27,262)(27,233)
Nonoperating income (expense)(1,828)1,1781,56677432513294
Investment income, nonoperating281,1781,56677432513294
Net loss available to common stockholders, diluted:(21,796)(61,389)(49,690)(30,879)(22,499)(27,130)(27,139)

Comprehensive Income ($ in thousands)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(21,796)(61,389)(49,690)(30,879)(22,499)(27,130)(27,139)
Comprehensive loss:(21,796)(61,389)(49,690)(30,879)(22,499)(27,130)(27,139)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(1)2420 19(23)(27)
Comprehensive loss, net of tax, attributable to parent:(21,797)(61,365)(49,670)(30,879)(22,480)(27,153)(27,166)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: